The Federal Competition Commission (CFC) has announced that it is barring Nestle SA from buying Pfizer Inc’d infant formula arm in Mexico, citing competition concerns. The deal would have been made for $11.85 billion, as Nestle outbid Groupe Danone SA last April to buy the infant formula business. The CFC determined that the eventual 71 percent stake in the sector for stage one and two formula, and an 88 percent stake for stage three formula, would be too much of a dominant position for Nestle. The CFC used quantitative techniques to come to its conclusion.
Featured News
DOJ Official Highlights Role of Antitrust and Intellectual Property in Driving US Innovation
Mar 26, 2026 by
CPI
US Judge Dismisses X Lawsuit Alleging Advertising Boycott
Mar 26, 2026 by
CPI
Congress Passes Bill to Unfreeze Billions in Small Business R&D Funding
Mar 26, 2026 by
CPI
EU Charges Major Adult Platforms Over Child Safety Failures Under Digital Services Act
Mar 26, 2026 by
CPI
European Regulators Target Snapchat Over Alleged Safety Failures
Mar 26, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Competitor Collaborations
Mar 26, 2026 by
CPI
Between Scylla and Charybdis – Navigating Transatlantic Antitrust Currents
Mar 26, 2026 by
Tilman Kuhn & Niklas Brüggemann
Cartel Enforcement Moves Into the Labor Market: Trends and Implications
Mar 26, 2026 by
Andreas Kafetzopoulos & Caroline Janssens
Rethinking Buy-Side Antitrust “Group Boycotts”
Mar 26, 2026 by
Craig Falls & Brendan McGuire
Positive Collaborations: The Tools Available to Competition Authorities to Encourage Beneficial Interactions Between Competitors
Mar 26, 2026 by
Rona Bar-Isaac & Thomas Withers